In participants with hemophilia B, fidanacogene elaparvovec was superior to factor IX prophylaxis, with a lower bleeding rate and stable factor IX expression.
The New England Journal of Medicine: Search Results in Pediatrics
Gene Therapy with Fidanacogene Elaparvovec in Adults with Hemophilia B
